FCCC LOGO Faculty Publications
Maifrede S , Le BV , Nieborowska-Skorska M , Golovine K , Sullivan-Reed K , Dunuwille WMB , Nacson J , Hulse M , Keith K , Madzo J , Caruso LB , Gazze Z , Lian Z , Padella A , Chitrala KN , Bartholdy BA , Matlawska-Wasowska K , Di Marcantonio D , Simonetti G , Greiner G , Sykes SM , Valent P , Paietta EM , Tallman MS , Fernandez HF , Litzow MR , Minden MD , Huang J , Martinelli G , Vassiliou GS , Tempera I , Piwocka K , Johnson N , Challen GA , Skorski T
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
Cancer Res. 2021 Oct 1;81(19) :5089-5101
PMID: 34215619    PMCID: PMC8487956    URL: https://www.ncbi.nlm.nih.gov/pubmed/34215619
Back to previous list
Abstract
Somatic variants in TET2 and DNMT3A are founding mutations in hematological malignancies that affect the epigenetic regulation of DNA methylation. Mutations in both genes often co-occur with activating mutations in oncogenic tyrosine kinases such as FLT3ITD, BCR-ABL1, JAK2V617F, and MPLW515L, or with mutations affecting related signaling pathways such as NRASG12D and CALRdel52. Here we show that TET2 and DNMT3A mutations exert divergent roles in regulating DNA repair activities in leukemia cells expressing these oncogenes. Malignant TET2-deficient cells displayed downregulation of BRCA1 and LIG4, resulting in reduced activity of BRCA1/2-mediated homologous recombination (HR) and DNA-PK -mediated non-homologous end-joining (D-NHEJ), respectively. TET2-deficient cells relied on PARP1-mediated alternative NHEJ (Alt-NHEJ) for protection from the toxic effects of spontaneous and drug-induced DNA double-strand breaks. Conversely, DNMT3A-deficient cells favored HR/D-NHEJ owing to downregulation of PARP1 and reduction of Alt-NHEJ. Consequently, malignant TET2-deficient cells were sensitive to PARP inhibitor (PARPi) treatment in vitro and in vivo, whereas DNMT3A-deficient cells were resistant. Disruption of TET2 dioxygenase activity or TET2 - Wilms tumor 1 (WT1) binding ability were responsible for DNA repair defects and sensitivity to PARPi associated with TET2 deficiency. Moreover, mutation or deletion of WT1 mimicked the effect of TET2 mutation on DSB repair activity and sensitivity to PARPi. Collectively, these findings reveal that TET2 and WT1 mutations may serve as biomarkers of synthetic lethality triggered by PARPi, which should be explored therapeutically.
Notes
1538-7445 Maifrede, Silvia Le, Bac Viet Orcid: 0000-0001-5077-8994 Nieborowska-Skorska, Margaret Golovine, Konstantin Sullivan-Reed, Katherine Dunuwille, Wangisa M B Nacson, Joseph Hulse, Michael Orcid: 0000-0002-6691-365x Keith, Kelsey Orcid: 0000-0002-7451-5117 Madzo, Jozef Orcid: 0000-0001-6607-1213 Caruso, Lisa Beatrice Gazze, Zachary Orcid: 0000-0002-5929-7414 Lian, Zhaorui Orcid: 0000-0001-9309-6379 Padella, Antonella Orcid: 0000-0001-9991-992x Chitrala, Kumaraswamy N Bartholdy, Boris A Orcid: 0000-0002-7401-8591 Matlawska-Wasowska, Ksenia Orcid: 0000-0002-9903-5793 Di Marcantonio, Daniela Simonetti, Giorgia Greiner, Georg Orcid: 0000-0002-0917-4117 Sykes, Stephen M Valent, Peter Paietta, Elisabeth M Tallman, Martin S Fernandez, Hugo F Litzow, Mark R Minden, Mark D Huang, Jian Martinelli, Giovanni Vassiliou, George S Tempera, Italo Piwocka, Katarzyna Johnson, Neil Challen, Grant A Orcid: 0000-0003-4669-8814 Skorski, Tomasz R01 CA214799/CA/NCI NIH HHS/United States R01 CA237286/CA/NCI NIH HHS/United States R01 GM135293/GM/NIGMS NIH HHS/United States Journal Article United States Cancer Res. 2021 Jul 2:canres.3761.2020. doi: 10.1158/0008-5472.CAN-20-3761.